In a multiregional clinical trial, researchers compared the safety and efficacy of once-weekly subcutaneous injections of semaglutide, an analog of glucagon-like peptide-1 (GLP-1), to once-daily injections of sitagliptin in patients with type 2 diabetes (T2D)
This may lead to symptoms like hot flashes and vaginal dryness
The short half-life (~15-30 minutes) means each injection provides an acute GH pulse rather than sustained elevation
Heres what sets us apart: Free Case Review Well review your medical history and explain whether you may qualify for a lawsuit
You can read more about the differences between Ozempic, Wegovy, Rybelsus, and compounded semaglutide in our guide here
Clinical evidence consistently demonstrates that patients regain approximately one-third of lost weight within the first year of stopping GLP-1 therapy, with longer-term studies suggesting even more substantial rebound [50]